MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market’s close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.
Help employers find you! Check out all the jobs and post your resume.
